TNX 1810
Alternative Names: TNX-1810Latest Information Update: 28 Jun 2024
At a glance
- Originator Tonix Pharmaceuticals Holding Corp
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA
- 07 May 2020 Tonix Pharmaceuticals and the University of Alberta agree to develop TNX 1810 for the prevention of COVID-19 infection
- 07 May 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route)